(function(){ var content_array=["

關于惠爾金<\/b>^{®<\/sup><\/b>（莫格利珠單抗）<\/b><\/p> \n}

惠爾金^{®<\/sup><\/b>是一款同類首創人源化單克隆抗體（mAb），旨在與C-C趨化因子受體4（CCR4）相結合。惠爾金^{®<\/sup><\/b>與CCR4結合后，會在人體免疫系統中激活更多的免疫細胞，進而破壞癌細胞^{[7]<\/span><\/sup>。惠爾金^{®<\/sup><\/b>使用協和麒麟專有的POTELLIGENT^{®<\/sup><\/b>技術，可增強人體對治療的自然免疫反應，從而提高對癌細胞的殺傷力。FDA已授予惠爾金^{®<\/sup><\/b>突破性療法和孤兒藥認定^{[19],[20<\/span>]<\/sup>。此外，惠爾金^{®<\/sup><\/b>還于2016年被歐盟委員會（EC）授予孤兒藥認定^{[21]<\/span><\/sup>。惠爾金^{®<\/sup><\/b>是首個也是唯一<\/span>在中國和世界其他地區獲批的靶向CCR4的生物制劑^{[22]<\/span><\/sup>。<\/p> \n}}}}}}}}}}}

*伏立諾他是美國FDA批準用于治療蕈樣肉芽腫和塞扎里綜合征的藥物，目前尚未在中國獲批<\/p> \n

參考文獻<\/b><\/p> \n

^{[1] Until July 2022<\/span>, the data source: Ding Xiang Yuan database.
<\/sup>^{[2] Placeholder (To be updated with NMPA approval news release)
<\/sup>^{[3] Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol<\/i>. 2018;19(9):1192-1204.
<\/sup>^{[4] Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol<\/i>. 2002;119:1405-10.
<\/sup>^{[5] Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood<\/i>. 2002;99(5):1505-11.
<\/sup>^{[6] Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia\/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res<\/span><\/i>. 2003;9:3625-34.
<\/sup>^{[7] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol<\/i>. 2016;7(3):171-174.
<\/sup>^{[8] Willemze R, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood<\/i>. 2019;133(16):1703-1714.
<\/sup>^{[9] Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood<\/i>. 2007;110(6):1713-22.
<\/sup>^{[10] Orphanet: Prevalence and incidence of rare diseases: Bibliographic data. Available from: https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf<\/a>. Last accessed: June 2020<\/span>.
<\/sup>^{[11] Orphanet: Mycosis Fungoides. Available from:}https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB&Expert=2584<\/a>. <\/u>Last Accessed: June 2020<\/span>.
<\/sup>^{[12] Orphanet: Sézary syndrome. Available from:}https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=3162<\/a>. Last Accessed: June 2020<\/span>.
<\/sup>^{[13] Haun P, et al. Fast Facts : Diagnosing Cutaneous T-Cell Lymphoma. Karger Publishing<\/i>. 2016.
<\/sup>^{[14] Cutaneous Lymphoma Foundation, Lymphoma Action and Lymphoma Coalition Europe. Cutaneous lymphoma – a patient's guide. 2019. Available from:}}https:\/\/lymphoma-action.org.uk\/sites\/default\/files\/media\/documents\/2019-06\/Cutaneous%20lymphoma%20-%20patient%26%23039%3Bs%20guide%20-%20English%20language%20source%20document%20-%20final%20version%20for%20publication%20-%20April%202019.pdf<\/a>. Last accessed: June 2020<\/span>.
<\/sup>^{[15] CL Foundation: A Patient's Guide. Available from:}https:\/\/www.clfoundation.org\/sites\/default\/files\/2018-04\/a_patients_guide.pdf<\/a>. Last Accessed: 18 November 2019<\/span>.
<\/sup>^{[16] Scarisbrick JJ, Prince M, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol<\/i>. 2015;33(32):3766-3773.
<\/sup>^{[17] Kim YH, Bagot M, Zinzani PL et al. Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood. 2019;134 (1):5300.
<\/sup>^{[18] Clin Lymphoma Myeloma Leuk. 2021 Feb; 21(2):97-105
<\/sup>^{[19] Search Orphan Drug Designations and Approvals (fda.gov). Available from}}}}https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=322010<\/a>. Last accessed: July 2022<\/span>.
<\/sup>^{[20] FDA approves treatment for two rare types of non-Hodgkin lymphoma. Available from:}https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-two-rare-types-non-hodgkin-lymphoma<\/a>. Last accessed: July 2022<\/span>.
<\/sup>^{[21] EU\/3\/16\/1756: Orphan designation for the treatment of cutaneous T-cell lymphoma. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3161756. Last accessed: July 2022<\/span>.<\/sup><\/p> \n}}}}}}}}}}}

<\/p>"]; $("#dvExtra").html(content_array[0]);})();

<center id="kgssg"></center>

<optgroup id="kgssg"></optgroup>

<center id="kgssg"></center>

久久久亚洲欧洲日产国码二区